We were delighted to catch up with Mr Alan Kirk (Golden Jubilee National Hospital, West Dunbartonshire, Scotland, UK) to discuss the 24-month follow-up to the TRANSFORM study, investigating endobronchial valve treatment for patients with severe heterogeneous emphysema.
The abstract ‘Durability of Zephyr Valve treatment: 24-month follow-up in the TRANSFORM Study.‘ (Presentation ID: 1201) was presented at ERS International Congress 2021, 5-8 September 2021.
Questions
- Can you briefly outline how the Zephyr Valve works and who the target population are? (0:15)
- What benefits were demonstrated with the Zephyr Valve over 6 months during the TRANSFORM study? (2:41)
- Were treatment benefits maintained over the 24-month follow-up to the TRANSFORM study? (3:57)
- What are the implications of these results for patients with severe heterogeneous emphysema? (5:00)
- What unmet needs still remain for patients with emphysema? (6:26)
Disclosures: Alan Kirk discloses receiving research funding from Pulmonx for TRANSFORM and CONVERT studies.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ERS 2021 (Virtual).
